A0AAU9YXB8 (A0AAU9YXB8_PHORO) Phodopus roborovskii (Roborovski's desert hamster) (Cricetulusroborovskii)

Mapk1 protein UniProtKBInterProInteractive Modelling

358 aa; Sequence (Fasta) ; 7 identical sequences: Rattus norvegicus: P63086, A6JSN9; Mus spicilegus: A0A8C6HGX0; Mus musculus: P63085; Mus caroli: A0A6P5R8X8; Mesocricetus auratus: A0A1U7QEZ9; Cricetulus griseus: A0A8C2QMB3

Available Structures

60 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
Crystal structure of a designed selected Ankyrin Repeat protein in complex with the phosphorylated … Heteromer
P63086;
3-358
100SO4;
Crystal structure of Erk2 complex with KIM peptide derived from MKP3 Heteromer
P63086; Q64346;
8-357
100.0
Crystal structure of rat ERK2 complexed with docking peptide from ISG20 Heteromer
P63086; Q96AZ6;
9-354
100.0ANP;
Crystal structure of ERK2/DCC peptide complex Heteromer
P63086; Q63155;
9-354
100.0SCN;
Docking motif interactions in the MAP kinase ERK2 Heteromer
P35236; P63086;
10-354
99.71
Crystal structure of a designed selected Ankyrin Repeat protein in complex with the MAP kinase ERK2 Heteromer
P63086;
10-353
100
COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52monomer2-358
99.72MG;ATP;
Structure of ERK2 (SPE) mutant (S246E)monomer4-358
99.71
PHOSPHORYLATED MAP KINASE ERK2monomer6-358
100
Crystal structure of mitogen-activated protein kinase 1 wtERK2 at 1.45Amonomer4-355
100.0
ERK2 R65S mutant complexed with AMP-PNPmonomer4-355
99.71ANP;SO4;MG;
ERK2 intrinsically active mutant (I84A)monomer4-355
99.71
Crystal structure of ERK2 AMP-PNP complexmonomer4-354
100.0ANP;SO4;MG;
ERK2 Intrinsically active mutant R65Smonomer4-354
99.71
ERK2 MAP kinase with mutations at Helix-Gmonomer3-353
99.11
STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASEmonomer4-354
100.0SO4;
ERK2 (I84A) in complex with AMP-PNPmonomer4-354
99.71SO4;ANP;MG;
THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025monomer6-355
100SB4;
Rat ERK2 E320Kmonomer7-356
100.0
THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINEmonomer6-355
100SO4;OLO;
A Double Mutant Rat Erk2 in Complex With a Pyrazolo[3,4-d]pyrimidine Inhibitormonomer8-356
99.422H1;
Crystal Structure of ERK-2 with hypothemycin covalently boundmonomer6-354
100.0HMY;
Rat ERK2 D319Nmonomer9-356
99.71SO4;
ATP-bound form of the ERK2 kinasemonomer9-356
100GOL;ATP;MG;PEG;
Monoclinic crystal form of the apo-ERK2monomer9-356
100.0GOL;SO4;PGE;
Crystal Structure of a Double Mutant Rat Erk2 Complexed With a Type II Quinazoline Inhibitormonomer9-356
99.4G17;
Dissecting Therapeutic Resistance to ERK Inhibition Rat Wild Type SCH772984 in complex with (3R)-1-…monomer9-355
10038Z;SO4;PG4;DMS;
Crystal structure of ERK2 in complex with an inhibitormonomer8-354
100.0SO4;DMS;42A;
Crystal structure of ERK2 in complex with an inhibitormonomer8-354
100.0Z8B; 11×DMS;SO4;BME;
Crystal structure of ERK2 in complex with an adenosine derivativemonomer8-354
100.0SO4;DF8;DMS;
Dissecting Therapeutic Resistance to ERK Inhibition Rat Mutant SCH772984 in complex with (3R)-1-(2-…monomer9-355
99.7138Z;SO4;
Crystal structure of ERK2 in complex with an inhibitormonomer8-354
100.0DX4;SO4; 11×DMS;
Crystal structure of ERK2 in complex with an adenosine derivativemonomer8-354
100.0SO4;AOC;
Crystal structure of ERK2 in complex with an inhibitormonomer8-354
100.0620;SO4;
Crystal structure of ERK2 in complex with an adenosine derivativemonomer8-353
100.0SO4;DQ2;DMS;
Crystal structure of ERK2 in complex with an inhibitormonomer9-354
100.06PB; 10×DMS;SO4;
Crystal structure of ERK2 in complex with an adenosine derivativemonomer8-353
100.0DMS;SO4;DJ2;
Crystal structure of ERK2 in complex with an adenosine derivativemonomer9-354
100.0DMS;SO4;ZAS;
Crystal structure of ERK2 in complex with an adenosine derivativemonomer9-354
100.0DMS;SO4;E9W;
Crystal structure of ERK2 in complex with an adenosine derivativemonomer9-354
100.0DMS;SO4;E3K;
Crystal structure of ERK2 in complex with an adenosine derivativemonomer9-354
100.0SO4;E2K;DMS;
Crystal structure of ERK2 in complex with an adenosine derivativemonomer9-354
100.0DMS;SO4;DU8;
Crystal structure of ERK2 in complex with an inhibitormonomer9-354
100620;SO4;
Crystal structure of ERK2 in complex with an inhibitormonomer8-353
100.0TT4;DMS;SO4;
Crystal structure of ERK2 in complex with an inhibitormonomer9-354
100TT4;SO4;
ADP-bound form of the ERK2 kinasemonomer11-356
100ADP;GOL;
Crystal structure of ERK2 in complex with an adenosine derivativemonomer9-354
100SO4;DKW;
Crystal structure of ERK2 in complex with an adenosine derivativemonomer9-354
100.0SO4;DTW;DMS;
Crystal structure of ERK2 in complex with an adenosine derivativemonomer9-354
100.0DVZ;DMS;SO4;
Phosphorylated ERK2 with Vertex-11emonomer9-354
100390;
Crystal structure of ERK2 in complex with an adenosine derivativemonomer9-353
100.0DMS;SO4;A3N;
Crystal structure of ERK2 in complex with an inhibitormonomer9-353
100.0DX4;SO4;
Crystal structure at room temperature of Erk2 in complex with an inhibitormonomer9-353
99.41SO4;42A;
ERK2 MAP kinase with the activation loop of p38alphamonomer12-355
100.0
Discovery of Novel, Dual Mechanism ERK Inhibitors by Affinity Selection Screening of an Inactive Ki…monomer13-353
100.03G7;SO4;
Discovery of 1-1H-Pyrazolo 4,3-c pyridine-6-yl urea Inhibitors of Extracellular Signal Regulated Ki…monomer16-355
1006S9;SO4;
Discovery of MLi-2, an Orally Available and Selective LRRK2 Inhibitor that Reduces Brain Kinase Act…monomer16-355
100.081Y;SO4;
Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncologymonomer16-355
100.0SO4;F8V;
Unphosphorylated Mitogen Activated Protein Kinase ERK2 in Complex with (4-{[5-Carbamoyl-4-(3-Methyl…monomer16-355
100.0SO4;S91;BME;
Discovery of MK-8353: An Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncologymonomer16-354
100.0SO4;G67;

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
6nbs.1.Amonomer0.898-354
KJ7;KJ4;100.00